Perceptions of Biosimilars Among Healthcare Providers in Saudi Arabia
Biosimilars are safe and effective treatments for chronic diseases such as cancer and rheumatoid arthritis. The Saudi Food and Drug Authority (SFDA) manages the quality and registration of biosimilars in the Kingdom of Saudi Arabia. However, disparities among regulatory authorities, such as the abse...
Saved in:
Main Authors: | Mohammed Alqahtani, Ahmed Al-jedai, Albert Wertheimer |
---|---|
Format: | Article |
Language: | English |
Published: |
University of Minnesota Libraries Publishing
2024-11-01
|
Series: | INNOVATIONS in Pharmacy |
Subjects: | |
Online Access: | https://pubs.lib.umn.edu/index.php/innovations/article/view/6371 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Innovator ranibizumab ComparEd to Biosimilar ranibizumab in combination with Expansile gas in submaculaR HemorrhaGe: the ICEBERG study
by: Debdulal Chakraborty, et al.
Published: (2025-01-01) -
Knowledge on the Use of Biosimilars in Hematological Malignancies Amongst Health Care Workers at a Tertiary Hospital in Northeast Nigeria
by: Rufai A. Dachi, et al.
Published: (2024-07-01) -
Effects of infliximab biosimilar on retinal microvasculature in Crohn’s disease patients evaluated by optical coherence tomography angiography
by: Hesham M. El Mazar, et al.
Published: (2025-01-01) -
A retrospective cohort study of biosimilar rituximab therapy in pemphigus: experience from a tertiary care hospital in North India
by: Sabha Mushtaq, et al.
Published: (2024-11-01) -
IS IT POSSIBLE TO USE BEVACIZUMAB BIOSIMILAR IN ALL INDICATIONS REGISTERED FOR ORIGINAL DRUG?
by: S. V. Orlov, et al.
Published: (2016-06-01)